Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: An analysis of mobilization and engraftment

British Journal of Haematology

Volumn 162, Issue 1, 2013, Pages 107-111

  Publicover, Amy ^a   Richardson, Deborah S ^a   Davies, Andrew ^a   Hill, Kate S ^a   Hurlock, Carol ^a   Hutchins, David ^a   Jenner, Matthew W ^a   Johnson, Peter W ^a   Lamb, Jane ^a   Launders, Harriet ^a   Mckeag, Nikki ^a   Newman, Joan ^a   Orchard, Kim H ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Biosimilar; Engraftment; Granulocyte colony stimulating factor; Mobilization; Stem cell harvest

Indexed keywords

CARBOPLATIN; CD34 ANTIGEN; CYTARABINE; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

ADULT; AGED; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COST CONTROL; DRUG EFFECT; ENGRAFTMENT; FEMALE; HUMAN; HUMAN CELL; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUTROPHIL COUNT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; BIOSIMILAR PHARMACEUTICALS; EUROPEAN UNION; FEMALE; GRAFT SURVIVAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 84879080850     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12345     Document Type: Article

References (13)

1. Andreola, G., Babic, A., Rabascio, C., Negri, M., Martinelli, G. & Laszlo, D. (2012) Plerixafor and Filgrastim XM02 (tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation. European Journal of Haematology, 88, 154-158.
2. EMEA Committee for Medicinal Products for Human Use (CHMP) (2005) Guideline on Similar Biological Medicinal Products. CHMP/437/04. European Medicines Agency, London. Available at: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf.
3. EMEA Committee for Medicinal Products for Human Use (CHMP) (2006a) Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues. EMEA/CHMP/BMWP/42832/2005. European Medicines Agency, London. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdf.
4. EMEA Committee for Medicinal Products for Human Use (CHMP) (2006b) Annex to Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues. Guidance on Similar Medicinal Products Containing Recombinant Granulocyte-Colony Stimulating Factor. EMEA/CHMP/BMWP/31329/2005. European Medicines Agency, London. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003955.pdf.
5. Ferro, H., Juni, M., Bello, R., Vidal, A., Diez, R. & Pavlovsky, S. (2009) Utilization study of filgrastim (Neutromax) during autologous haematopoietic precursor transplantation for myeloma and lymphoma patients. Transfusion and Apheresis Science, 41, 87-93.
6. Laricchia-Robbio, L., Moscato, S., Genua, A., Liberati, A. & Revoltella, R. (1997) Naturally occurring and therapy-induced antibodies to human granulocyte colony-stimulating factor (G-CSF) in human serum. Journal of Cellular Physiology, 173, 219-226.
7. Lefrère, F., Brignier, A., Elie, C., Ribeil, J., Bernimoulin, M., Aoun, C., Dal Cortivo, L., Delarue, R., Hermine, O. & Cavazzana-Calvo, M. (2011) First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony-stimulating factor. Advances in Therapy, 28, 304-310.
8. Mellstedt, H., Niederwieser, D. & Ludwig, H. (2008) The challenge of biosimilars. Annals of Oncology, 19, 411-419.
9. Publicover, A., Richardson, D.S., Hill, K., Hurlock, C., Casey, P., Newman, J., Davies, A. & Orchard, K. (2010) Use of biosimilar granulocyte colony stimulating factor (GCSF) for peripheral blood progenitor cell mobilisation prior to autologous stem cell transplant: a single centre experience. Bone Marrow Transplantation, 45, S158-S159.
10. Schmitt, M., Xu, X., Hilgendorf, I., Schneider, C., Borchert, K., Gläser, D., Freund, M. & Schmitt, A. (2013) Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors. Bone Marrow Transplantation, doi:10.1038/bmt.2012.270.
11. Shaw, B., Confer, D., Hwang, W., Pamphilon, D. & Pulsipher, M. (2011) Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association. Haematologica, 96, 942-947.
12. Wadhwa, M., Bird, C., Dilger, P., Gaines-Das, R. & Thorpe, R. (2003) Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals. Journal of Immunological Methods, 278, 1-17.
13. WHO Expert Committee on Biological Standardization (2009) Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs). World Health Organization, Geneva, Switzerland.